Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
about
A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic MiceClinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patientsAssessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaBMP-7 attenuates adverse cardiac remodeling mediated through M2 macrophages in prediabetic cardiomyopathyNesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice.Combination immunotherapies for type 1 diabetes mellitus.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.Saxagliptin Attenuates Albuminuria by Inhibiting Podocyte Epithelial- to-Mesenchymal Transition via SDF-1α in Diabetic Nephropathy.Sitagliptin protects proliferation of neural progenitor cells in diabetic mice.Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.A Mouse Model of Beta-Cell Dysfunction as Seen in Human Type 2 Diabetes.Altered gene expression of amyloid precursor protein in the adipose tissue and brain of obese mice fed with long-term high-fat diet and streptozotocin-induced diabetic mice
P2860
Q27301757-92A939C6-1D99-43D9-A401-76B2A11EF292Q28083144-C33869D1-C251-4BCD-85FE-7C864FB64681Q33732627-EF77A6B3-36E3-4FDA-BBC8-F1CF0BCBEDD8Q34041974-F6C37319-A3A3-4E02-86EE-0AD6F175C9F4Q34296727-63172D67-5876-452E-B82C-4E4359B2764FQ35082454-6A0D4A5D-CD7B-49B5-A6E3-89CD0B47EE58Q38358009-37EBBB4E-FFF9-49E2-9B36-3D77EA9EC7A1Q38468017-5CD520FF-54E2-491F-944F-50DA5CC3AE35Q43159888-749BF5F8-7605-4323-A533-FAFCD026A469Q44120755-40A4B71A-6F90-4A9E-8C6B-670E53177331Q47099497-DDB2D6F0-20DB-44EE-9EDD-5B7D0C8546A2Q48321628-E46CC05A-42EA-48F8-A796-19550220F22CQ48379621-6D2E5049-1E8B-4999-9CB1-AF2F87F149B3Q52780711-9AB1EB9B-E31D-429A-ABEE-8905B3586950Q55100432-6582E4EF-9AC8-47AA-B9AB-156C39A7D517Q58189504-360072CF-AE0F-4E17-BA35-E29450A3FF3D
P2860
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@ast
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@en
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@nl
type
label
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@ast
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@en
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@nl
prefLabel
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@ast
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@en
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@nl
P2093
P2860
P1476
Effects of saxagliptin and sit ...... ouse model of type 2 diabetes.
@en
P2093
P2860
P304
P356
10.1111/J.1463-1326.2012.01619.X
P577
2012-05-28T00:00:00Z